## Full year result highlights

12 months to 31 March 2014

<table>
<thead>
<tr>
<th>Description</th>
<th>NZ$M</th>
<th>△ PCP</th>
<th>△ CC¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Record net profit after tax</td>
<td>97.1</td>
<td>+26%</td>
<td>+46%</td>
</tr>
<tr>
<td>Record operating revenue</td>
<td>623.4</td>
<td>+12%</td>
<td>+13%</td>
</tr>
<tr>
<td>Record RAC operating revenue</td>
<td>336.9</td>
<td>+12%</td>
<td>+14%</td>
</tr>
<tr>
<td>Record OSA operating revenue</td>
<td>270.0</td>
<td>+15%</td>
<td>+15%</td>
</tr>
<tr>
<td>RAC new applications consumables revenue</td>
<td></td>
<td>+26%</td>
<td>+29%</td>
</tr>
<tr>
<td>OSA masks revenue</td>
<td></td>
<td>+22%</td>
<td>+23%</td>
</tr>
<tr>
<td>Gross Margin (bps increase)</td>
<td></td>
<td>+327</td>
<td>+393</td>
</tr>
</tbody>
</table>

1. CC = constant currency
## Second half result highlights

6 months to 31 March 2014

<table>
<thead>
<tr>
<th></th>
<th>△PCP</th>
<th>△CC¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net profit after tax</td>
<td>+20%</td>
<td>+53%</td>
</tr>
<tr>
<td>Operating revenue</td>
<td>+10%</td>
<td>+14%</td>
</tr>
<tr>
<td>Gross margin (bps increase)</td>
<td>+247</td>
<td>+423</td>
</tr>
<tr>
<td>RAC new applications consumables revenue</td>
<td>+23%</td>
<td>+27%</td>
</tr>
<tr>
<td>OSA mask revenue</td>
<td>+22%</td>
<td>+26%</td>
</tr>
</tbody>
</table>

1. CC = constant currency
Innovative products driving growth

• Respiratory & Acute Care
  – Optiflow™ oxygen therapy system
  – Evaqua™2 breathing circuits
  – AIRVO™2 & myAIRVO™2 humidifiers with integrated flow generators

• Obstructive Sleep Apnea
  – Simplus™ full face mask
  – Eson™ nasal mask
  – Pilairo Q™ nasal pillows mask
  – ICON™+ flow generator range
## Full year operating results

**FY14** (12 months to 31 March 2014)

<table>
<thead>
<tr>
<th></th>
<th>%Revenue</th>
<th>NZ$M</th>
<th>△PCP</th>
<th>△CC&lt;sup&gt;1&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating revenue</td>
<td>100%</td>
<td>623.4</td>
<td>+12%</td>
<td>+13%</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>41.4%</td>
<td>258.0</td>
<td>+4%</td>
<td>+4%</td>
</tr>
<tr>
<td>Gross profit</td>
<td>58.6%</td>
<td>365.4</td>
<td>+19%</td>
<td>+22%</td>
</tr>
<tr>
<td>Other income (R&amp;D grant)</td>
<td></td>
<td>3.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SG&amp;A</td>
<td>27.5%</td>
<td>171.5</td>
<td>+13%</td>
<td>+14%</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>8.7%</td>
<td>54.1</td>
<td>+18%</td>
<td>+18%</td>
</tr>
<tr>
<td>Total operating expenses</td>
<td>36.2%</td>
<td>225.6</td>
<td>+14%</td>
<td>+15%</td>
</tr>
<tr>
<td>Operating profit</td>
<td>23.0%</td>
<td>143.5</td>
<td>+27%</td>
<td>+46%</td>
</tr>
<tr>
<td>Profit after tax</td>
<td>15.6%</td>
<td>97.1</td>
<td>+26%</td>
<td>+46%</td>
</tr>
</tbody>
</table>

1. CC = **constant currency**
Dividend

• Final dividend for the 2014 financial year:
  
  – 7.0 cps + 2.7 cps imputation credit for New Zealand residents (gross dividend of 9.7 NZ cps)
  – Fully imputed
  – 1.235 cps non-resident supplementary dividend
  – Dividend Reinvestment Plan offered for New Zealand and Australian residents - 3% discount

• Gross dividend yield, 17.2 cps ~4.1%
• Operating revenue growth
  - NZ$ +9%
  - Constant currency +13%

• New applications consumables revenue growth
  (Noninvasive ventilation (NIV), Optiflow, AIRVO, Surgical)
  - NZ$ +23%
  - Constant currency +27%

• New applications consumables now make up 42% of RAC consumables revenue, up from 38% in FY13

• More customers are choosing to use our Optiflow oxygen therapy system as the economic and health benefits are emerging
Obstructive sleep apnea (OSA)

- Operating revenue growth
  - NZ$: +13%
  - Constant currency: +17%

- Mask revenue growth
  - Constant currency: +26%

- Our Eson, Pilairo Q and Simplus masks are designed for comfort, seal and ease of use and have been very well received by our customers. All are now available in the majority of our key markets.

H2 FY2014
FY14 (as at 31 March 2014)

<table>
<thead>
<tr>
<th></th>
<th>NZ$M</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating cash flow</td>
<td>104.1</td>
</tr>
<tr>
<td>Capital expenditure</td>
<td>31.9</td>
</tr>
<tr>
<td>Depreciation and amortisation</td>
<td>29.9</td>
</tr>
<tr>
<td>Net debt</td>
<td>98.9</td>
</tr>
<tr>
<td>Total shareholders equity</td>
<td>406.1</td>
</tr>
<tr>
<td>Total assets</td>
<td>630.3</td>
</tr>
</tbody>
</table>

- 34% pre-tax return on equity, 22% on total assets
Foreign exchange effects

- NZ$360.4M of hedging in place at 31 March 2014 for FY15.
- 48% of operating revenue in USD (FY13: 50%) and 24% in €. As direct sales operations increase an increasing proportion of our revenue is generated in local currencies, reducing operating revenue exposure to USD.

- Hedging position for our main exposures:

<table>
<thead>
<tr>
<th></th>
<th>Year to 31 March</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
</tr>
<tr>
<td>USD % cover of expected exposure</td>
<td>53%</td>
</tr>
<tr>
<td>USD average rate of cover</td>
<td>0.78</td>
</tr>
<tr>
<td>EUR % cover of expected exposure</td>
<td>81%</td>
</tr>
<tr>
<td>EUR average rate of cover</td>
<td>0.50</td>
</tr>
</tbody>
</table>

- Previously closed out forex contracts
  - NZ$21.3M to operating profit in FY14, zero in FY15
Outlook FY15

• Operating profit headwind of NZ$32 million in FY15 from reduced hedging and less favourable spot rates

• Expect to again deliver robust constant currency net profit growth of approximately 40% for FY15

• Expect at a NZD:USD exchange rate of 0.86
  – Operating revenue – approximately NZ$640 million
  – Net profit after tax – approximately NZ$97 million
Investment highlights

• A leader in respiratory and OSA treatment devices

• Consistent growth strategy

• Estimated US$5.0+ billion and growing market opportunity

• High level of innovation

• Global presence

• Strong financial performance NZSX:FPH, ASX:FPH
Markets & products

- Respiratory & Acute Care (RAC)
  - Heated humidification
  - Respiratory care
  - Neonatal care
  - Surgery

- Obstructive Sleep Apnea (OSA)
  - Masks
  - Flow generators
  - Data management tools
  - Humidifiers

- Consumable and accessory products represent approximately 78% of core product revenue (FY13: 76%)

Revenue by Product Group
12 months to 31 March 2014
Hospital cost breakdown

- Labour: 70%
- Drugs, Devices, Supplies & Food: 21%
- Utilities, Depreciation: 9%

Source: Massachusetts Hospital Association, “An Update to Hospital Costs in Context Report” July 2010
Lower care intensity equals lower cost

Mean Annual COPD-Related Medical, Pharmacy, and Total Costs by Care Intensity Cohort

Respiratory humidification

- Normal airway humidification is bypassed or compromised during ventilation or oxygen therapy
- Mucociliary transport system operates less effectively
- Need to deliver gas at physiologically normal levels
  - 37 °C body core temperature
  - 44mg/L 100% saturated
Therapies - respiratory care, acute care & surgical

- Invasive ventilation
- Noninvasive ventilation
- Oxygen therapy
- Humidity therapy

- Neonatal invasive ventilation
- Neonatal noninvasive ventilation
- Neonatal oxygen therapy
- Surgical humidification

- Evaqua 2™
- FreeMotion™
- Optiflow™
- AIRVO™ 2

- F&P
- Evaqua 2™
- Bubble CPAP
- Optiflow™ junior
- HumiGard™
Respiratory & acute care - hardware

- 850 respiratory humidifier system
  - Invasive ventilation, oxygen therapy and non-invasive ventilation
- 810 respiratory humidifier system
  - Entry level system
  - Ventilation and oxygen therapy
  - Optional heated breathing circuit
- AIRVO 2 flow generator/humidifier
  - Optiflow oxygen therapy
  - Humidity therapy
- Surgical opportunity (HumiGard)
  - Laparoscopic insufflation
  - Open surgery
Respiratory & acute care - single use consumables

• Single-use chambers
  – Patented auto filling MR290
• Single-use breathing circuits
  – Patented spiral heater wire
  – Proprietary Evaqua 2 expiratory tube
  – Minimal condensation
  – Delivery of optimal humidity
• Breathing circuit components
  – Filters, catheter mount, weaning kit
• Interfaces
  – NIV masks, tracheostomy, Optiflow, oxygen therapy
• Approx 30 system set-ups used per controller per year
• Consumable growth driving revenue growth
Obstructive sleep apnea

• Temporary closure of airway during sleep

• Can greatly impair quality of sleep, leading to fatigue; also associated with hypertension, stroke and heart attack

• Estimated US$2.5+ billion worldwide market, growing approximately 6 - 8%

• Potentially 50-60 million affected worldwide

• Most common treatment is CPAP (Continuous Positive Airway Pressure)
  - Key issue with CPAP is compliance
  - Humidification provides significant acceptance and compliance improvements
Revolutionary masks

• Comfortable
• Easy to fit
• Efficient
Stylish, smart + simplified CPAP range

• Efficiently integrates with InfoUSB and InfoSmart Web
• Responsive pressure relief - SensAwake
• ThermoSmart humidifier breathing tube technology
• Auto-adjusting CPAP
Efficient compliance reporting
Research & development

• 8.7% of operating revenue, NZ$54.1M\(^1\)

• Product pipeline includes:
  – Humidifier controllers
  – Masks
  – Respiratory consumables
  – Flow generators
  – Compliance monitoring solutions

• 111 US patents, 220 US pending, 459 ROW, 306 ROW pending\(^1\)

\(^1\) at 31 March 2014
Manufacturing & operations

• Vertically integrated
  – COGs improvements; Mexico, Lean manufacturing, supply chain

• Ample capacity to grow

Auckland, New Zealand
  – Three buildings: 82,000 m² / 885,000 ft² total
  – 100 acres/40ha land

Tijuana, Mexico
  – 18,000 m² / 200,000 ft²
  – Consumables capacity ramping up
Global presence

• Direct/offices
  – Hospitals, home care dealers
  – Sales/support offices in North America, Europe, Asia, South America, Middle East and Australasia, 15 distribution centres
  – More than 600 staff in 30 countries
  – Ongoing international expansion

• Distributors
  – 100+ distributors worldwide

• Original Equipment Manufacturers
  – Supply most leading ventilator manufacturers
  – More than 120 countries in total

Revenue by region
12 months to 31 March 2014
Consistent growth strategy

• Experts in humidification, respiratory care, and obstructive sleep apnea

• Provide innovative devices which can improve patient care and outcomes

Continuous product improvement

More devices for each patient

Serve more patient groups – invasive ventilation, NIV, oxygen therapy, COPD, surgery, OSA

Increase international presence